Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
posidinemab
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Posidinemab (JNJ-63733657) is a humanized IgG1 monoclonal antibody designed to target the microtubule-associated protein tau (MAPT), specifically binding to pathological tau species. Developed by Janssen Research & Development (a subsidiary of Johnson & Johnson), it is being investigated for the treatment of early Alzheimer's disease. The mechanism involves binding to pathological tau aggregates to prevent their trans-neuronal spread (the seeding hypothesis), thereby potentially slowing cognitive and functional decline. It is currently being evaluated in Phase 2 clinical trials, including the Autonomy study, which focuses on patients with early-stage Alzheimer's disease.
- Other names
- posidinemab
02
Targets
p-tau (Phosphorylated microtubule-associated protein tau)
Beyond the preview
Go deeper on posidinemab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on posidinemab.